Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

The curves show simple linear regression lines. *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.000 1Demographic and clinical characteristics (mean ± SD) of the patients at baseline (n = 50)CharacteristicAge/year62.18 ± 10.74Sex, no. (%) Male9 (18.00%) Female41 (82.00%)Race, no. (%) White41 (82.00%) Black or African American2 (4.00%) Asian2 (4.00%) More than one race0 Other5 (10.00%)Ethnic group, no. (%) Hispanic7 (14.00%) Non-Hispanic42 (84.00%) Unknown1 (2.00%)Body-mass indexa24.93 ± 4.06Bone mineral density T scores Lumbar spine−1.77 ± 1.54 Total hip−1.55 ± 1.11 Femoral neck−1.90 ± 1.13 Distal 1/3 radius−1.72 ± 1.56Osteoporosis, no. (%)15 (30.00%)Osteopenia, no. (%)18 (36.00%)Normal bone density, no. (%)17 (34.00%)History of fracture, no. (%)b Yes31 (62.00%) No19 (38.00%)Screening lab valuescSerum calcium (8.6 to 10.4 mg/dL)10.61 ± 0.71Serum PTH (15.1 to 85.7 pg/mL)78.12 ± 31.18Serum 25OHD (>20 ng/mL)34.53 ± 12.57Serum CTX (0.14 to 1.35 ng/mL)0.80 ± 0.46Serum P1NP/(ng/mL)71.00 ± 33.56aThe body-mass index is the weight in kilograms divided by the square of the height in metersbExcludes fractures of the skull, face, fingers, and toes, which are typically not associated with osteoporosis, as well as fractures associated with high trauma severitycNumbers in parentheses are the reference rangeDemographic and clinical characteristics (mean ± SD) of the stool donor patients utilized for FMT studiesCharacteristicNormal BMDOsteopeniaOsteoporosisAge/year62.50 ± 10.0257.25 ± 7.9369.75 ± 8.57Sex, no. (%) Male1 (25.00%)00 Female3 (75.00%)4 (100.00%)4 (100.00%)Race, no. (%) White4 (100.00%)2 (50.00%)3 (75.00%) Black or African American01 (25.00%)0 Asian001 (25.00%) More than one race000 Other01 (25.00%)0Ethnic group, no. (%) Hispanic01 (25.00%)0 Non-Hispanic4 (100.00%)3 (75.00%)4 (100.00%) Unknown000Body-mass indexa25.68 ± 4.9124.35 ± 4.4020.83 ± 2.07Bone mineral density T scores Lumbar spine0.42 ± 0.71−1.85 ± 0.40**−4.47 ± 0.81**** Total hip−0.52 ± 0.28−1.27 ± 0.70−2.95 ± 1.19** Femoral neck−0.82 ± 0.92−1.65 ± 0.65−3.15 ± 0.91* Distal 1/3 radius−0.72 ± 1.10−0.80 ± 1.46*−3.90 ± 0.57**History of fracture, no. (%)b3 (75.00%)2 (50.00%)1 (25.00%)Screening lab valuescSerum calcium (8.6 to 10.4 mg/dL)10.33 ± 0.9711.08 ± 0.8211.30 ± 0.86Serum PTH (15.1 to 85.7 pg/mL)96.23 ± 11.8971.83 ± 12.47107.1 ± 56.88Serum 25OHD (>20 ng/mL)24.29 ± 7.9135.56 ± 13.9830.52 ± 10.77Serum CTX (0.14 to 1.35 ng/mL)0.87 ± 0.560.79 ± 0.341.23 ± 1.00Serum P1NP/(μg/L)93.05 ± 51.8092.05 ± 28.4987.03 ± 33.54*P < 0.05, **P < 0.01, and ****P < 0.001 compared to normal BMD groupaThe body-mass index is the weight in kilograms divided by the square of the height in metersbExcludes fractures of the skull, face, fingers, and toes, which are typically not associated with osteoporosis, as well as fractures associated with high trauma severitycNumbers in parentheses are the reference range

Source: The gut microbiome of primary hyperparathyroidism patients is a transmissible regulator of bone density. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Study design awaiting verification.

Study design awaiting verification

The available source does not establish a sufficiently clear study design.

Meta-analysis unclear · Blinding unclear / not reported · Mixed research settings

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

Men and women aged 30 to 85 were eligible for inclusion if they had a confirmed diagnosis of primary hyperparathyroidism at screening.

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Bacterial specificity of the gut microbiome predicts bone density in primary hyperparathyroidism

Study design awaiting verification · Bone Research · 2026

Original publication title

Bacterial specificity of the gut microbiome predicts bone density in primary hyperparathyroidism

Hamid Y. Dar; Jiali Fang; Sanchiti Patil; Nand K. Roy; Sanchita Agarwal; M. Neale Weitzmann; Rheinallt M. Jones; John P. Bilezikian; Roberto Pacifici

© The Author(s) 2026

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

At a glance

What does the authors’ abstract report?

Primary hyperparathyroidism causes mild-to-severe bone loss, but the reason for this heterogeneity is unclear. We investigated the role of the microbiome in 50 primary hyperparathyroidism patients. Microbiome transfers from primary hyperparathyroidism patients with and without osteoporosis to germ-free mice replicated the human bone phenotype and regulated TNF+ T cells and Th17 cells in mice. Accordingly, circulating TNF+ T cells and Th17 cells and TNF/IL17 production predicted bone density in primary hyperparathyroidism patients. Bifidobacterium longum, TNF+ T cells, and Th17 cells were mediators of bone loss in primary hyperparathyroidism patients, while Bifidobacterium longum supplementation caused PTH to expand TNF+ T cells and Th17 cells and induce bone loss in mice.

Our findings link Bifidobacterium longum-induced TNF+ T cells and Th17 cells to bone loss in patients with primary hyperparathyroidism. Bifidobacterium longum abundance may determine the skeletal phenotypes of patients with primary hyperparathyroidism and allow prediction of their risk of bone loss. Microbiome modifications by antibiotics or precision probiotics might offer novel preventive approaches for the skeletal complications of primary hyperparathyroidism.

Authors’ abstract

Primary hyperparathyroidism causes mild-to-severe bone loss, but the reason for this heterogeneity is unclear. We investigated the role of the microbiome in 50 primary hyperparathyroidism patients. Microbiome transfers from primary hyperparathyroidism patients with and without osteoporosis to germ-free mice replicated the human bone phenotype and regulated TNF+ T cells and Th17 cells in mice. Accordingly, circulating TNF+ T cells and Th17 cells and TNF/IL17 production predicted bone density in primary hyperparathyroidism patients. Bifidobacterium longum, TNF+ T cells, and Th17 cells were mediators of bone loss in primary hyperparathyroidism patients, while Bifidobacterium longum supplementation caused PTH to expand TNF+ T cells and Th17 cells and induce bone loss in mice.

Our findings link Bifidobacterium longum-induced TNF+ T cells and Th17 cells to bone loss in patients with primary hyperparathyroidism. Bifidobacterium longum abundance may determine the skeletal phenotypes of patients with primary hyperparathyroidism and allow prediction of their risk of bone loss. Microbiome modifications by antibiotics or precision probiotics might offer novel preventive approaches for the skeletal complications of primary hyperparathyroidism.

Publication and source details

Original title: Bacterial specificity of the gut microbiome predicts bone density in primary hyperparathyroidism

Hamid Y. Dar; Jiali Fang; Sanchiti Patil; Nand K. Roy; Sanchita Agarwal; M. Neale Weitzmann; Rheinallt M. Jones; John P. Bilezikian; Roberto Pacifici

Bone Research · 2026

© The Author(s) 20262026https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.https://doi.org/10.13039/100000002U.S. Department of Health & Human Services | National Institutes of Health (NIH)DK124821DK124821Bilezikian John P. Pacifici Roberto

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-10T22:27:25.441930+00:00

DOI: 10.1038/s41413-026-00529-1 · PMC13201753